Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Pemazyre | pemigatinib | Cholangiocarcinoma | Do not reimburse | Complete | ||
| Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Active | ||
| Myinfla | colchicine | Atherothrombotic events in coronary artery disease | Do not reimburse | Complete | ||
| Humira | Adalimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
| Lodalis | Colesevelam hydrochloride | Hypercholesterolemia | Do not list at the submitted price | Complete | ||
| Dificid | Fidaxomicin | Clostridium difficile infection | Do not list at the submitted price | Complete | ||
| Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete | ||
| Bystolic | Nebivolol | Hypertension | Do not list at the submitted price | Complete | ||
| Edarbi | Azilsartan medoxomil | Hypertension | Do not list at the submitted price | Complete | ||
| Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete |
Last Updated : May 18, 2024